BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27

• 

  Mark Deming

  Mark Deming is an intellectual property attorney at Polsinelli. His practice includes pharmaceutical and medical device patent litigation.
• 

  Policy

  FDA Brings Back Previously Disbanded Generic Drug Policy Panel

  The reinstatement of the generic drug policy office is the latest reversal of course for Robert F. Kennedy Jr.'s HHS, which also recently rehired FDA staff responsible for making travel arrangements and those involved in user fee program negotiations.

  June 10, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Vaccines

  ‘More Critical’ Vaccine Advisors Expected Following Kennedy’s ACIP Ouster

  Robert F. Kennedy Jr.’s removal of all remaining members of the CDC’s Advisory Committee on Immunization Practices raises questions about the upcoming meeting later this month. Analysts fear the committee could be more sympathetic to the HHS Secretary’s anti-vax viewpoints.

  June 10, 2025

   · 

  3 min read

   · 

  Heather McKenzie
• 

  Infectious disease

  Gilead’s HIV Combo on Hold, With No Impact on FDA’s Pending Lenacapavir Decision

  Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused five clinical trials. Gilead also stressed that the hold does not impact any other assets in its HIV pipeline.

  June 10, 2025

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  RSV

  Merck Wins FDA Nod for RSV Antibody, Tees Up Challenge to Sanofi, AstraZeneca

  Merck’s Enflonsia will go up against Sanofi and AstraZeneca’s Beyfortus, which the partners plan to ship out early in the third quarter.

  June 10, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Layoffs

  Recursion Downsizes by 20% To Boost Cash Position

  As of March 31, Recursion Pharmaceuticals had a cash position of $509 million. Following Tuesday’s layoffs, the biotech expects its runway to last into the fourth quarter of 2027.

  June 10, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  IPO

  Odyssey Ends Quest for Nasdaq, Pulls IPO Application After Nearly 5 Months

  Odyssey filed for an IPO in January but never revealed a fundraising target.

  June 10, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Special edition

  Deep Dive: Top Paid Pharma Execs—and Those Who Would Get the Most to Leave

  BioSpace did a deep dive into executive pay, examining the highest compensation packages, pay ratios and golden parachutes—what a CEO would get paid to leave.

  June 10, 2025

   · 

  2 min read

   · 

  Annalee Armstrong
• Press Releases

  Solventum Launches Preassembled, See-through VH2O2 Test Pack for Low-temp Medical Instrument Sterilization

  June 10, 2025

   · 

  7 min read
• Press Releases

  Catheter Precision, Inc. Secures VIVO Purchase Order From Sahlgrenska University Hospital

  June 10, 2025

   · 

  2 min read